US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

18.92

+0.24001.28%

Post-market: 18.920.00000.00%16:10 EDT

Volume:414.19K

Turnover:7.80M

Market Cap:1.20B

PE:-8.50

High:19.12

Open:18.57

Low:18.30

Close:18.68

52wk High:20.25

52wk Low:7.80

Shares:63.19M

Float Shares:24.13M

Volume Ratio:0.73

T/O Rate:1.72%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.97

PE(LYR):-4.68

Loading ...

Overview Company News Filings

BofA Initiates Bicara Therapeutics at Buy With $35 Price Target

MT Newswires Live

Bicara Therapeutics Initiated at Buy by B of A Securities

Bicara Therapeutics initiated with a Buy at BofA

Calendar of U.S. Earnings Expected in the Week Ahead

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Bicara CFO Ivan Hyep disposed of USD 170,348 of common shares

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

Calendar of U.S. Earnings Expected in the Week Ahead

Bicara Therapeutics CEO Claire Mazumdar disposed of USD 282,000 in common shares

Bicara Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

Bicara Therapeutics President and COO Ryan Cohlhepp disposes of USD 245,714 in common shares

Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares

Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares

Bicara Therapeutics CFO Ivan Hyep Disposes of Common Shares

Bicara Therapeutics Chief Medical Officer David Raben Disposes of Common Shares

Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug

Simply Wall St.

Bicara Therapeutics announces inducement grants

BRIEF-Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Bicara Therapeutics Grants New Hire Stock Option for 115,000 Shares Under 2026 Inducement Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":18.92,"timestamp":1774555200000,"preClose":18.68,"halted":0,"volume":414188,"hourTrading":{"tag":"盘后","latestPrice":18.92,"preClose":18.92,"latestTime":"16:10 EDT","volume":29425,"amount":556716.8805,"timestamp":1774555805016,"change":0,"changeRate":0,"amplitude":0.001057},"delay":0,"changeRate":0.012847965738758137,"floatShares":24134000,"shares":63193700,"eps":-2.227112,"marketStatus":"Post-Mkt","change":0.24,"latestTime":"03-26 16:12:53 EDT","open":18.57,"high":19.115,"low":18.295,"amount":7804514.662464,"amplitude":0.043897,"askPrice":22,"askSize":60,"bidPrice":15.03,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":18.68,"preHourTrading":{"tag":"盘前","latestPrice":18.61,"preClose":18.68,"latestTime":"08:36 EDT","volume":528,"amount":9807.739392,"timestamp":1774528613938,"change":-0.07,"changeRate":-0.003747,"amplitude":0.261242},"postHourTrading":{"tag":"盘后","latestPrice":18.92,"preClose":18.92,"latestTime":"16:10 EDT","volume":29425,"amount":556716.8805,"timestamp":1774555805016,"change":0,"changeRate":0,"amplitude":0.001057},"volumeRatio":0.734285,"impliedVol":0.0607,"impliedVolPercentile":0.0359},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134000,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":0.734285,"shares":63193700,"dividePrice":0,"high":19.115,"amplitude":0.043897,"preClose":18.68,"low":18.295,"week52Low":7.8,"pbRate":"2.97","week52High":20.25,"institutionHeld":0,"latestPrice":18.92,"committee":0.25,"eps":-2.227112,"divideRate":0,"volume":414188,"delay":0,"ttmEps":-2.227112,"open":18.57,"prevYearClose":16.83,"prevWeekClose":18.41,"prevMonthClose":16.78,"prevQuarterClose":16.83,"fiveDayClose":18.79,"twentyDayClose":16.8,"sixtyDayClose":16.51,"earningDate":1774800000000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"BCAX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"defaultRemindTime":1774857600000,"name":null,"time":"Pre-Market","dateTimestamp":1774843200000,"actualEps":null},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5,"hold":0.2143,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1770868800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-03-25","current":-8.387544,"percent":0.45288,"low":-22.704836,"twenty":-15.064521,"median":-9.055544,"eighty":-6.584246,"high":-5.144536,"avg":-10.587375,"sd":4.599263,"marketCap":1179804352},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-25","current":-9.708646,"twenty":-15.064521,"median":-9.055544,"eighty":-6.584246,"marketCap":1179804352}],"updateTime":1774515843159},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622506074","title":"BofA Initiates Bicara Therapeutics at Buy With $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2622506074","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622506074?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:04","pubTimestamp":1774447461,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $29.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"2622760600","title":"Bicara Therapeutics Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2622760600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622760600?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:58","pubTimestamp":1774443480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 08:58 ET (12:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2622022366","title":"Bicara Therapeutics initiated with a Buy at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2622022366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622022366?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:10","pubTimestamp":1774433452,"startTime":"0","endTime":"0","summary":"BofA initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $35 price target Published first on TheFly – the ultimate source for re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","FEMY","KALV","CMC","MKC","CGNT","EQ","HYPD","AGX","HUMA","JEF","EPAC","BYND","BIRD","NKE","CCL","DOO","AURA","RNXT","BAK","CHWY","IKT","IMNN","BCAX","ABOS","BTGO","JBS","IMDX","CELC","CTAS","FDS","CNTX","GOVX","EDAP","KOD","BHST","AIRO","AIRJ","CNTB","DERM","FUL","BNZI","JILL","CDLR","DMAC","AUTL","BITF","DEFT","CNTA"],"gpt_icon":1},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","AMZN","BWXT","AIR","DK","CEGX","BCAX","DINO","FRPT","AZYY","BXP","CVI","AMZP","CEG","FIGG","ELVN","BTM","BP","AARD","FANG","KBH","AFG","GLW","INSM","AMZD","BRZE","ABSI","BPH","AMZU","FIG","AVAH","ACAD","AVTX","EVGO","APEI","CVX","ARE","BZAI","CALM","HAL","CNM","HD","GENB","USAW.SI","MTDR","BAM","DG","ADUS","ESE"],"gpt_icon":1},{"id":"2622014384","title":"Bicara CFO Ivan Hyep disposed of USD 170,348 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014384","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622014384?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:45","pubTimestamp":1774395930,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics, reported an option exercise for 9,200 common shares at USD 3.79 per share.He also reported selling 9,200 common shares at a weighted average price of USD 18.52 per share.Following the transactions, he beneficially owned 145,355 common shares.After the option exercise, he held 48,944 stock options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5Q42FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara CFO Ivan Hyep disposed of USD 170,348 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2621672705","title":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2621672705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621672705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:30","pubTimestamp":1774269000,"startTime":"0","endTime":"0","summary":"BOSTON, March  23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260367/0/en/Bicara-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates-on-March-30-2026-at-8-30-AM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4144","AM","ET","BK4590","BK4581","BK4139","IE00BZ18W340.USD","IE00BZ18W456.USD","BK4585","BK4561","BK4588","IE00BMQBXF63.USD"],"gpt_icon":0},{"id":"2621583774","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2621583774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621583774?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:00","pubTimestamp":1774260000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","GOVX","FEMY","FENC","AIR","IMDX","BYND","KALV","ACHV","BZAI","CNM","EVTL","EDAP","DPRO","HYPD","ABOS","EQ","KBH","AVTX","CNTA","MXCT","IMNN","BRZE","DEFT","DERM","BAK","DOO","ABVX","CNXC","CNTX","AGX","IKT","JEF","CCL","JBS","HUMA","EPAC","CELC","GUTS","FBRX","CNTB","CTAS","FUL","ABSI","BTGO","HSAI","AUTL","CMC","CHWY","CGNT"],"gpt_icon":0},{"id":"2621544287","title":"Bicara Therapeutics CEO Claire Mazumdar disposed of USD 282,000 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621544287","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621544287?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:03","pubTimestamp":1774040624,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer and director of Bicara Therapeutics, reported transactions in common stock on March 18, 2026.She acquired 6,499 shares at USD 3.79 and disposed of 6,499 shares at USD 18.84.Additional transactions were reported on March 19, 2026, involving 6,905 shares acquired at USD 3.79 and 6,905 shares disposed of at USD 18.78.On March 20, 2026, she acquired 1,596 shares at USD 3.79 and disposed of 1,596 shares at USD 18.95.Following the reported transactions, she beneficially owned 339,392 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL3G3qhF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CEO Claire Mazumdar disposed of USD 282,000 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2620790733","title":"Bicara Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620790733","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620790733?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:09","pubTimestamp":1774008545,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Bicara Therapeutics Inc BCAX.OQ BCAX.O is expected to  show no change in quarterly revenue when it reports  result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40811C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2620782840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782840?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:00","pubTimestamp":1774000800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRMN","EVTL","CNTA","ALMS","CMC","BZAI","ACHV","FUFU","BAK","FEMY","GUTS","CTAS","ABSI","BCAX","KBH","CHWY","AIR","DERM","DOO","CNTB","JBS","MXCT","EDAP","JEF","FENC","FUL","HSAI","GOVX","HUMA","CNXC","BTGO","CUK","ABVX","EPAC","CGNT","CELC","FBRX","AGX","KALV","IMNN","AVTX","EQ","CNTX","CNM","KOD","BRZE","HYPD","BYND","IKT"],"gpt_icon":1},{"id":"2620057034","title":"Bicara Therapeutics President and COO Ryan Cohlhepp disposes of USD 245,714 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620057034","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620057034?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:37","pubTimestamp":1773783449,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics, reported a disposal of 12,500 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7lV4KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics President and COO Ryan Cohlhepp disposes of USD 245,714 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2618975049","title":"Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618975049","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618975049?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:48","pubTimestamp":1773262116,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer and director of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL94jhdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2617656110","title":"Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617656110","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617656110?lang=en_us&edition=fundamental","pubTime":"2026-03-07 08:28","pubTimestamp":1772843286,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer and director of Bicara Therapeutics Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260307:nNDL93VR6z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2617577774","title":"Bicara Therapeutics CFO Ivan Hyep Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577774","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617577774?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:09","pubTimestamp":1772755760,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL4D5hlk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2617457774","title":"Bicara Therapeutics Chief Medical Officer David Raben Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617457774","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617457774?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:07","pubTimestamp":1772755624,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL1QqSMd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics Chief Medical Officer David Raben Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2616755998","title":"Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2616755998","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616755998?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:32","pubTimestamp":1772634722,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics recently completed a follow-on equity offering of about US$150.00 million in common stock and pre-funded warrants to support late-stage development and potential commercialization of its lead cancer therapy, ficerafusp alfa.\nThis financing follows encouraging Phase 1b data and Breakthrough Therapy Designation for ficerafusp alfa in head and neck cancer, underscoring how Bicara is positioning itself for future regulatory milestones and commercialization efforts.\nNext,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/why-bicara-therapeutics-bcax-is-up-103-after-us150-million-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/why-bicara-therapeutics-bcax-is-up-103-after-us150-million-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2616555865","title":"Bicara Therapeutics announces inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2616555865","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616555865?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:37","pubTimestamp":1772631452,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) awarded an inducement grant on March 2, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material induc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-announces-inducement-grants-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-announces-inducement-grants-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2616784553","title":"BRIEF-Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616784553?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:33","pubTimestamp":1772631219,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara TherapeuticsAnnounces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)March 4 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA1V3S00:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2616553780","title":"Bicara Therapeutics Grants New Hire Stock Option for 115,000 Shares Under 2026 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616553780?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:30","pubTimestamp":1772631011,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. granted a new employee a non-qualified stock option to buy 115,000 shares at an exercise price of $17.59 per share, matching the March 2, 2026 Nasdaq closing price. The award was made under the company’s 2026 Inducement Plan, adopted in January 2026, with one-quarter vesting on the first anniversary of the employee’s start date and the remainder vesting in 12 equal quarterly installments, subject to continued service.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5GDW8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","BCAX","LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","BK4139","LU2095319765.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":104,"code":"91000000","status":"200"}]}}